<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04213807</url>
  </required_header>
  <id_info>
    <org_study_id>ANT-004</org_study_id>
    <nct_id>NCT04213807</nct_id>
  </id_info>
  <brief_title>A Dose-range Finding Study of MAA868 in Patients With Atrial Fibrillation</brief_title>
  <official_title>A Randomized, Placebo-controlled, Dose-range Finding Study to Assess the Pharmacokinetic and Pharmacodynamic Parameters, Safety, Tolerability, and Immunogenicity of MAA868 in Patients With Atrial Fibrillation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Anthos Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Covance</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Anthos Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a multicenter, randomized, subject and Investigator-blinded,&#xD;
      placebo-controlled, parallel-group, multiple ascending dose-ranging study to evaluate the&#xD;
      safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) effects of MAA868 in&#xD;
      patients with atrial fibrillation (AF) or flutter at low risk of thromboembolic stroke or&#xD;
      peripheral embolism.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 11, 2019</start_date>
  <completion_date type="Actual">March 8, 2021</completion_date>
  <primary_completion_date type="Actual">December 29, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Inhibition of FXI at trough after third dose (Day 91) at different dose levels of MAA868</measure>
    <time_frame>Day 91</time_frame>
    <description>Occurrence of achieving ≥50%, ≥80%, or ≥90% inhibition of FXI (&lt;50%, &lt;20%, or &lt;10% free FXI) at trough on Day 91 at different dose levels of MAA868</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Inhibition of FXI at trough after first and second dose (Day 31 and Day 61) at different dose levels of MAA868</measure>
    <time_frame>Day 31 and Day 61</time_frame>
    <description>Occurrence of achieving ≥50%, ≥ 80%, and ≥90% inhibition of FXI (&lt;50%, &lt;20%, or &lt;10% free FXI) at trough on Day 31 and Day 61 at different dose levels of MAA868</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of adverse events following multiple subcutaneous administration of MAA868 compared to placebo in patients with atrial fibrillation</measure>
    <time_frame>Day 1 through end of study, up to 170 days</time_frame>
    <description>Occurrence of adverse events (AEs), including serious adverse events (SAEs) during the treatment period and through end of study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of major bleeding events, clinically relevant non-major (CRNM) bleeding events and total bleeding with MAA868 relative to placebo</measure>
    <time_frame>Day 1 through end of study, up to 170 days</time_frame>
    <description>Occurrence of confirmed major bleeding events, clinically relevant non-major (CRNM) bleeding events and total bleeding events during the treatment period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity of MAA868 compared to placebo</measure>
    <time_frame>Days 1, 31, 61, 71, 91, 121 and 170</time_frame>
    <description>Screening and confirmation for anti-drug (MAA868) antibodies</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>MAA868</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subcutaneous injection on Day 1 with two subsequent monthly injections</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subcutaneous injection: Placebo on Day 1 with two subsequent monthly injections</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MAA868 Cohort 1</intervention_name>
    <description>Subcutaneous injection: low dose</description>
    <arm_group_label>MAA868</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MAA868 Cohort 2</intervention_name>
    <description>Subcutaneous injection: high dose</description>
    <arm_group_label>MAA868</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MAA868 Cohort 3</intervention_name>
    <description>Subcutaneous injection: Dose to be determined</description>
    <arm_group_label>MAA868</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Subcutaneous injection: Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male and female patients ≥ 18 and &lt; 85 years old with paroxysmal atrial fibrillation&#xD;
             (PAF) or atrial flutter on 12 lead electrocardiography at Screening Or&#xD;
&#xD;
          -  Patients with a history of PAF or atrial flutter, as documented by (telemetry, 12 lead&#xD;
             electrocardiography or ambulatory [e.g. Holter] monitor) and not due to a reversible&#xD;
             condition (e.g. alcohol binge drinking) can be entered even if they do not have PAF at&#xD;
             Screening. There is not time-limit for this.&#xD;
&#xD;
          -  Patients with a Congestive heart failure, Hypertension, Age ( &gt; 65 = 1 point, &gt; 75 = 2&#xD;
             points), Diabetes, previous Stroke/transient ischemic attack (2 points) (CHA2DS2-VASc)&#xD;
             risk score (tool as a predictor for estimating the risk of stroke in patients with&#xD;
             atrial fibrillation (AF); Lip et al 2010) of 0-1 for men and 1-2 for women and in&#xD;
             whom, in the investigator's judgment, the use of an anticoagulant for stroke&#xD;
             prevention is not indicated&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of stroke, transient ischemic attack or systemic embolism&#xD;
&#xD;
          -  History of major bleeding during treatment with an anticoagulant or antiplatelet&#xD;
             therapy. (Patients who have had major bleeding on anticoagulants or antiplatelet&#xD;
             therapy more than a year ago can be enrolled only if the bleeding was due to a&#xD;
             reversible cause, e.g. gastro-duodenal ulcer that was successfully treated.)&#xD;
&#xD;
          -  History of traumatic or non-traumatic intracranial, intraspinal or intraocular&#xD;
             bleeding&#xD;
&#xD;
          -  Known bleeding diathesis or any known active bleeding site at screening or baseline&#xD;
&#xD;
          -  Family history of bleeding disorder&#xD;
&#xD;
          -  Known active GI lesions predisposing to bleeding events&#xD;
&#xD;
          -  Myocardial infarction, unstable angina pectoris or coronary artery bypass graft (CABG)&#xD;
             surgery within 12 months prior to the Screening period&#xD;
&#xD;
          -  Known clinically significant valvular heart disease including moderate or severe&#xD;
             mitral stenosis (valve area &lt;1.5 cm2)&#xD;
&#xD;
          -  Patients with a prosthetic heart valve&#xD;
&#xD;
        Other protocol defined Inclusion/Exclusion criteria may apply&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Norman E Lepor, MD FACC FAHA FSCAI</last_name>
    <role>Principal Investigator</role>
    <affiliation>Westside Medical Associates of Los Angeles</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Anthos Investigative Site</name>
      <address>
        <city>Beverly Hills</city>
        <state>California</state>
        <zip>90211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Anthos Investigative Site</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Anthos Investigative Site</name>
      <address>
        <city>Alexandria</city>
        <state>Louisiana</state>
        <zip>71301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Anthos Investigative Site</name>
      <address>
        <city>Lansing</city>
        <state>Michigan</state>
        <zip>48912</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Anthos Investigative Site</name>
      <address>
        <city>Wynnewood</city>
        <state>Pennsylvania</state>
        <zip>19096</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Anthos Investigative Site</name>
      <address>
        <city>McKinney</city>
        <state>Texas</state>
        <zip>75069</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>December 23, 2019</study_first_submitted>
  <study_first_submitted_qc>December 26, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 30, 2019</study_first_posted>
  <last_update_submitted>March 23, 2021</last_update_submitted>
  <last_update_submitted_qc>March 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>atrial fibrillation</keyword>
  <keyword>flutter</keyword>
  <keyword>paroxysmal atrial fibrillation</keyword>
  <keyword>stroke</keyword>
  <keyword>cardiac arrhythmia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <pending_results>
    <submitted>November 9, 2021</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

